Loading...
•
Jun 30, 2020
ANI Pharmaceuticals Q2 2020 Earnings Report
ANI Pharmaceuticals reported a net loss of $12.3 million and adjusted non-GAAP diluted earnings per share of $0.69 for Q2 2020.
Key Takeaways
ANI Pharmaceuticals reported a decrease in net revenues to $48.5 million for the second quarter of 2020, compared to $54.5 million in the same period of 2019. The company experienced a net loss of $12.3 million, compared to a net income of $6.6 million in the prior year period. Adjusted non-GAAP diluted earnings per share was $0.69, down from $1.44 in the second quarter of 2019. The results were impacted by the COVID-19 pandemic and increased operating expenses.
Net revenues for Q2 2020 were $48.5 million, compared to $54.5 million in Q2 2019.
Net loss for Q2 2020 was $12.3 million, compared to net income of $6.6 million in the prior year period.
Adjusted non-GAAP diluted earnings per share was $0.69 in Q2 2020, compared to $1.44 in the prior year period.
Nikhil Lalwani was named President and CEO, effective September 8, 2020.
ANI Pharmaceuticals
ANI Pharmaceuticals
ANI Pharmaceuticals Revenue by Segment
Revenue by Segment
Brands Revenue
CapyFin.comGeneric Pharmaceutical Products Revenue
CapyFin.com Forward Guidance
Due to inherent uncertainties regarding the duration and impact of the COVID-19 pandemic, ANI has suspended its previously announced 2020 financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income